KPP-III-51

KPP-III-51 is a synthetic small molecule analog of the GABAkine KRM-II-81, developed as a potential anticonvulsant with reduced sedative effects. It acts as an agonist at **GABAA receptors**, binding to brain GABAARs to enhance inhibitory neurotransmission. Initially developed by the **University of Wisconsin-Milwaukee**, it demonstrated oral bioavailability in rodents but lower plasma and brain exposures compared to the parent compound. Unlike related analogs, intraperitoneal administration did not produce anticonvulsant activity in mouse models of maximal electroshock or 6 Hz seizures, limiting its preclinical advancement.[1][3][10]